Aripiprazole as protector against COVID-19 mortality.

Humans Aripiprazole / therapeutic use COVID-19 / mortality Male Female Antipsychotic Agents / therapeutic use Middle Aged Retrospective Studies Aged SARS-CoV-2 / drug effects COVID-19 Drug Treatment Adult Aged, 80 and over
Antipsychotics COVID-19 Mortality SARS-CoV-2

Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
29 May 2024
Historique:
received: 21 11 2023
accepted: 21 04 2024
medline: 30 5 2024
pubmed: 30 5 2024
entrez: 29 5 2024
Statut: epublish

Résumé

The relation of antipsychotics with severe Coronavirus Disease 19 (COVID-19) outcomes is a matter of debate since the beginning of the pandemic. To date, controversial results have been published on this issue. We aimed to prove whether antipsychotics might exert adverse or protective effects against fatal outcomes derived from COVID-19. A population-based retrospective cohort study (January 2020 to November 2020) comprising inpatients (15,968 patients) who were at least 18 years old and had a laboratory-confirmed COVID-19 infection. Two sub-cohorts were delineated, comprising a total of 2536 inpatients: individuals who either had no prescription medication or were prescribed an antipsychotic within the 15 days preceding hospitalization. We conducted survival and odds ratio analyses to assess the association between antipsychotic use and mortality, reporting both unadjusted and covariate-adjusted results. We computed the average treatment effects, using the untreated group as the reference, and the average treatment effect on the treated, focusing solely on the antipsychotic-treated population. Among the eight antipsychotics found to be in use, only aripiprazole showed a significant decrease in the risk of death from COVID-19 [adjusted odds ratio (OR) = 0.86; 95% CI, 0.79-0.93, multiple-testing adjusted p-value < 0.05]. Importantly, these findings were consistent for both covariate-adjusted and unadjusted analyses. Aripiprazole has been shown to have a differentiated beneficial effect in protecting against fatal clinical outcome in COVID-19 infected individuals. We speculate that the differential effect of aripiprazole on controlling immunological pathways and inducible inflammatory enzymes, that are critical in COVID19 illness, may be associated with our findings herein.

Identifiants

DOI: 10.1038/s41598-024-60297-y PMID: 38811612
pubmed: 38811612
doi: 10.1038/s41598-024-60297-y
pii: 10.1038/s41598-024-60297-y
doi:

Substances chimiques

Aripiprazole 82VFR53I78
Antipsychotic Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

12362

Informations de copyright

© 2024. The Author(s).

Références

Clinical, Biological and Molecular Aspects of COVID-19. Vol. 1321 (2021).
Dyer, O. Covid-19: Infections climb globally as EG.5 variant gains ground. BMJ 382, 1900 (2023).
doi: 10.1136/bmj.p1900 pubmed: 37586736
Weekly Epidemiological Update on COVID-19—17 August 2023. https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---17-august-2023 (2023).
Weekly Epidemiological Update on COVID-19—10 August 2023. https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---10-august-2023 (2023).
Weekly Epidemiological Update on COVID-19—3 August 2023. https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---3-august-2023 (2023).
Weekly Epidemiological Update on COVID-19—27 July 2023. https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---27-july-2023 (2023).
Canal-Rivero, M. et al. The impact of COVID-19 pandemic on the psychological well-being among health care workers: A 6-month cohort longitudinal survey study. Rev. Psiquiatr. Salud Ment. 16, 25–37 (2023).
doi: 10.1016/j.rpsm.2022.08.001 pubmed: 36039175
Jansen van Vuren, E. et al. The neuropsychiatric manifestations of COVID-19: Interactions with psychiatric illness and pharmacological treatment. Biomed. Pharmacother. 135, 33 (2021).
doi: 10.1016/j.biopha.2020.111200
Macdonald, O. et al. Impact of the COVID-19 pandemic on antipsychotic prescribing in individuals with autism, dementia, learning disability, serious mental illness or living in a care home: A federated analysis of 59 million patients’ primary care records in situ using OpenSAFELY. BMJ Ment. Health 26, 300775 (2023).
doi: 10.1136/bmjment-2023-300775
Fico, G. et al. Psychotropic drug repurposing for COVID-19: A systematic review and meta-analysis. Eur. Neuropsychopharmacol. 66, 30 (2023).
doi: 10.1016/j.euroneuro.2022.10.004 pubmed: 36399837
Vai, B. et al. Mental disorders and risk of COVID-19-related mortality, hospitalisation, and intensive care unit admission: A systematic review and meta-analysis. Lancet Psychiatry 8, 797–812 (2021).
doi: 10.1016/S2215-0366(21)00232-7 pubmed: 34274033 pmcid: 8285121
Canal-Rivero, M. et al. Lower risk of SARS-CoV2 infection in individuals with severe mental disorders on antipsychotic treatment: A retrospective epidemiological study in a representative Spanish population. Schizophr. Res. 229, 53–54 (2021).
doi: 10.1016/j.schres.2021.02.002 pubmed: 33631466 pmcid: 7894093
Nemani, K. et al. Association between the use of psychotropic medications and the risk of COVID-19 infection among long-term inpatients with serious mental illness in a New York State-wide Psychiatric Hospital System. JAMA Netw. Open 5, 2210743 (2022).
doi: 10.1001/jamanetworkopen.2022.10743
Mangalmurti, N. & Hunter, C. A. Cytokine storms: Understanding COVID-19. Immunity 53, 19 (2020).
doi: 10.1016/j.immuni.2020.06.017 pubmed: 32610079 pmcid: 7321048
Dinesh, A. A., Islam, J., Khan, J., Turkheimer, F. & Vernon, A. C. Effects of antipsychotic drugs: Cross talk between the nervous and innate immune system. CNS Drugs 34, 1229–1251 (2020).
doi: 10.1007/s40263-020-00765-x pubmed: 32975758
Obuchowicz, E., Bielecka-Wajdman, A. M., Paul-Samojedny, M. & Nowacka, M. Different influence of antipsychotics on the balance between pro- and anti-inflammatory cytokines depends on glia activation: An in vitro study. Cytokine 94, 37–44 (2017).
doi: 10.1016/j.cyto.2017.04.004 pubmed: 28411046
Kato, T., Monji, A., Hashioka, S. & Kanba, S. Risperidone significantly inhibits interferon-gamma-induced microglial activation in vitro. Schizophr. Res. 92, 108–115 (2007).
doi: 10.1016/j.schres.2007.01.019 pubmed: 17363222
Juncal-Ruiz, M. et al. The effect of excess weight on circulating inflammatory cytokines in drug-naïve first-episode psychosis individuals. J. Neuroinflamm. 15, 63 (2018).
doi: 10.1186/s12974-018-1096-6
Boland, X. & Dratcu, L. Antipsychotics and COVID-19: The debate goes on. Lancet Psychiatry 8, 1030 (2021).
doi: 10.1016/S2215-0366(21)00396-5 pubmed: 34801118 pmcid: 8601681
Canal-Rivero, M. et al. Epidemiology of infection, transmission and COVID-19 outcomes among mental health users and workers in a comprehensive network of long-term mental health facilities: Retrospective observational population-base study. Schizophr. Res. 254, 1 (2023).
doi: 10.1016/j.schres.2023.01.020 pubmed: 36736100 pmcid: 9852313
Muñoyerro-Muñiz, D. et al. Health record linkage: Andalusian health population database. Gac Sanit. 34, 105–113 (2020).
doi: 10.1016/j.gaceta.2019.03.003 pubmed: 31133300
Crespo-Facorro, B. et al. Aripiprazole as a candidate treatment of COVID-19 identified through genomic analysis. Front. Pharmacol. 12, 346. https://doi.org/10.3389/fphar.2021.646701 (2021).
doi: 10.3389/fphar.2021.646701
Canal-Rivero, M. et al. The role of antipsychotics against COVID-19: A topic for debate. Schizophr. Res. 235, 5–6 (2021).
doi: 10.1016/j.schres.2021.07.003 pubmed: 34274797 pmcid: 8264567
Hoertel, N. et al. Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: Results from an observational study. Mol. Psychiatry 26, 5199–5212 (2021).
doi: 10.1038/s41380-021-01021-4 pubmed: 33536545
Loucera, C. et al. Real world evidence of calcifediol or vitamin D prescription and mortality rate of COVID-19 in a retrospective cohort of hospitalized Andalusian patients. Sci. Rep. 11, 23380 (2021).
doi: 10.1038/s41598-021-02701-5 pubmed: 34862422 pmcid: 8642445
Sterne, J. A. C. et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: A meta-analysis. JAMA 324, 1330–1341 (2020).
doi: 10.1001/jama.2020.17023 pubmed: 32876694
World Medical Association declaration of Helsinki. Ethical principles for medical research involving human subjects. JAMA. https://doi.org/10.1001/jama.2013.281053 (2013).
doi: 10.1001/jama.2013.281053
von Elm, E. et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. J. Clin. Epidemiol. 61, 344 (2008).
doi: 10.1016/j.jclinepi.2007.11.008
Zeileis, A. Object-oriented computation of sandwich estimators. J. Stat. Softw. 16, 1–16 (2006).
doi: 10.18637/jss.v016.i09
Therneau, T. M. survival: A Package for Survival Analysis in R. R Package Version 2.38 (2021).
Greifer, N. Package ‘ cobalt ’. R Package Version (2016).
Therneau, T. M. & Grambsch, P. M. Modeling survival data : Extending the Cox model (2000).
Drawing Survival Curves Using ‘ggplot2’ [R package survminer version 0.4.9] (2021).
Create ‘Table 1’ to Describe Baseline Characteristics with or Without Propensity Score Weights [R package tableone version 0.13.2] (2022).
Zeileis, A., Köll, S. & Graham, N. Various versatile variances: An object-oriented implementation of clustered covariances in r. J. Stat. Softw. 95, 1 (2020).
doi: 10.18637/jss.v095.i01
Weston, S. et al. Broad anti-coronavirus activity of food and drug administration-approved drugs against SARS-CoV-2 in vitro and SARS-CoV in vivo. J. Virol. 94, 21 (2020).
doi: 10.1128/JVI.01218-20
Giridharan, V. V. et al. Clozapine prevents poly (I:C) induced inflammation by modulating NLRP3 pathway in microglial cells. Cells 9, 577 (2020).
doi: 10.3390/cells9030577 pubmed: 32121312
Riva, G. et al. COVID-19: More than a cytokine storm. Crit. Care 24, 549 (2020).
doi: 10.1186/s13054-020-03267-w pubmed: 32887652 pmcid: 7472946
Racki, V., Marcelic, M., Stimac, I., Petric, D. & Kucic, N. Effects of haloperidol, risperidone, and aripiprazole on the immunometabolic properties of BV-2 microglial cells. Int. J. Mol. Sci. 22, 9 (2021).
doi: 10.3390/ijms22094399
Hoertel, N. et al. Association between FIASMA psychotropic medications and reduced risk of intubation or death in individuals with psychiatric disorders hospitalized for severe COVID-19: An observational multicenter study. Transl. Psychiatry 12, 1 (2022).
doi: 10.1038/s41398-022-01804-5
Carpinteiro, A. et al. Pharmacological inhibition of acid sphingomyelinase prevents uptake of SARS-CoV-2 by epithelial cells. Cell Rep. Med. 1, 100142 (2020).
doi: 10.1016/j.xcrm.2020.100142 pubmed: 33163980 pmcid: 7598530
Kornhuber, J., Hoertel, N. & Gulbins, E. The acid sphingomyelinase/ceramide system in COVID-19. Mol. Psychiatry 27, 307–314 (2021).
doi: 10.1038/s41380-021-01309-5 pubmed: 34608263 pmcid: 8488928
Harrison, S. L., Buckley, B. J. R., Lane, D. A., Underhill, P. & Lip, G. Y. H. Associations between COVID-19 and 30-day thromboembolic events and mortality in people with dementia receiving antipsychotic medications. Pharmacol. Res. 167, 105534 (2021).
doi: 10.1016/j.phrs.2021.105534 pubmed: 33677103 pmcid: 9759831
McKeigue, P. M. et al. Relation of severe COVID-19 to polypharmacy and prescribing of psychotropic drugs: The REACT-SCOT case–control study. BMC Med. 19, 1–11 (2021).
Poblador-Plou, B. et al. Baseline chronic comorbidity and mortality in laboratory-confirmed COVID-19 cases: Results from the PRECOVID study in Spain. Int. J. Environ. Res. Public Health 17, 5171 (2020).
doi: 10.3390/ijerph17145171 pubmed: 32709002 pmcid: 7400393
Hoertel, N. et al. Observational study of haloperidol in hospitalized patients with COVID-19. PLoS One 16, e0247122 (2021).
doi: 10.1371/journal.pone.0247122 pubmed: 33606790 pmcid: 7895415
Ohlis, A. et al. Clozapine treatment and risk of severe COVID-19 infection. Acta Psychiatr. Scand. 145, 79–85 (2022).
doi: 10.1111/acps.13379 pubmed: 34676888

Auteurs

C Loucera-Muñecas (C)

Computational Medicine Platform, Andalusian Public Foundation Progress and Health-FPS, Seville, Spain.
Computational Systems Medicine, Institute of Biomedicine of Seville (IBiS), University Hospital Virgen del Rocío, Consejo Superior de Investigaciones Científicas, University of Seville, Seville, Spain.

M Canal-Rivero (M)

Hospital Universitario Virgen del Rocío, Av. Manuel Siurot, s/n, 41013, Sevilla, Spain. mcanal-ibis@us.es.
Centro Investigación Biomédica en Red Salud Mental, CIBERSAM, Madrid, Spain. mcanal-ibis@us.es.
Instituto de Biomedicina de Sevilla (IBiS), HUVR/CSIC/Universidad de Sevilla, Seville, Spain. mcanal-ibis@us.es.

M Ruiz-Veguilla (M)

Hospital Universitario Virgen del Rocío, Av. Manuel Siurot, s/n, 41013, Sevilla, Spain.
Centro Investigación Biomédica en Red Salud Mental, CIBERSAM, Madrid, Spain.
Instituto de Biomedicina de Sevilla (IBiS), HUVR/CSIC/Universidad de Sevilla, Seville, Spain.
Department of Psychiatry, Universidad de Sevilla, Seville, Spain.

R Carmona (R)

Computational Medicine Platform, Andalusian Public Foundation Progress and Health-FPS, Seville, Spain.
Computational Systems Medicine, Institute of Biomedicine of Seville (IBiS), University Hospital Virgen del Rocío, Consejo Superior de Investigaciones Científicas, University of Seville, Seville, Spain.

G Bostelmann (G)

Computational Medicine Platform, Andalusian Public Foundation Progress and Health-FPS, Seville, Spain.
Computational Systems Medicine, Institute of Biomedicine of Seville (IBiS), University Hospital Virgen del Rocío, Consejo Superior de Investigaciones Científicas, University of Seville, Seville, Spain.

N Garrido-Torres (N)

Hospital Universitario Virgen del Rocío, Av. Manuel Siurot, s/n, 41013, Sevilla, Spain.
Centro Investigación Biomédica en Red Salud Mental, CIBERSAM, Madrid, Spain.
Instituto de Biomedicina de Sevilla (IBiS), HUVR/CSIC/Universidad de Sevilla, Seville, Spain.

J Dopazo (J)

Computational Medicine Platform, Andalusian Public Foundation Progress and Health-FPS, Seville, Spain.
Computational Systems Medicine, Institute of Biomedicine of Seville (IBiS), University Hospital Virgen del Rocío, Consejo Superior de Investigaciones Científicas, University of Seville, Seville, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Seville, Spain.
FPS, ELIXIR-Es, Hospital Virgen del Rocío, Seville, Spain.

B Crespo-Facorro (B)

Hospital Universitario Virgen del Rocío, Av. Manuel Siurot, s/n, 41013, Sevilla, Spain.
Centro Investigación Biomédica en Red Salud Mental, CIBERSAM, Madrid, Spain.
Instituto de Biomedicina de Sevilla (IBiS), HUVR/CSIC/Universidad de Sevilla, Seville, Spain.
Department of Psychiatry, Universidad de Sevilla, Seville, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Aripiprazole as protector against COVID-19 mortality.
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › Quinoléines › Quinolinone › Aripiprazole › Aripiprazole as protector against COVID-19 mortality.
questionsmedicales.fr › Maladies de l'appareil respiratoire › Infections de l'appareil respiratoire › Pneumopathie infectieuse › Pneumopathie virale › COVID-19 › Aripiprazole as protector against COVID-19 mortality.
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Agents du système nerveux central › Psychoanaleptiques › Tranquillisants › Neuroleptiques › Aripiprazole as protector against COVID-19 mortality.
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Aripiprazole as protector against COVID-19 mortality.
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › Aripiprazole as protector against COVID-19 mortality.
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Aripiprazole as protector against COVID-19 mortality.
questionsmedicales.fr › Virus › Virus à ARN › Virus à ARN à brin positif › Nidovirales › Coronaviridae › Coronavirus › Betacoronavirus › Virus du SRAS › SARS-CoV-2 › Aripiprazole as protector against COVID-19 mortality.
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Traitements médicamenteux de la COVID-19 › Aripiprazole as protector against COVID-19 mortality.
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Aripiprazole as protector against COVID-19 mortality.
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Sujet âgé de 80 ans ou plus › Aripiprazole as protector against COVID-19 mortality.